SCHEMBL3563433

SCHEMBL3563433

O=C(O)c1ccc(OCCOc2ccc(Nc3ccc(F)cc3)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.60
PKM P14618 1/20 0.60
MITF O75030 1/20 0.53
TSHR P16473 2/20 0.51
MAPK1 P28482 2/20 0.51
USP2 O75604 1/20 0.51
ALOX15 P16050 1/20 0.51
HSD17B10 Q99714 1/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
TP53 P04637 1/20 0.50
FAAH O00519 1/20 0.49
PLA2G4B P0C869 2/20 0.49
ALDH1A1 P00352 2/20 0.49
POLB P06746 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
BCL2L1 Q07817 1/20 0.49
BAD Q92934 1/20 0.49
RARB P10826 1/20 0.48
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11446632 0.86 NR4A2 (0.59) NR4A2PKMMITFTSHRMAPK1
SCHEMBL9335896 0.85 NR4A2 (0.57) NR4A2PKMMITFTSHRMAPK1
SCHEMBL5460566 0.85 MITF (0.69) NR4A2MITFTSHRMEN1KMT2A
SCHEMBL3553373 0.82 AR (0.62) NR4A2MEN1KMT2APOLB
SCHEMBL196110 0.81 PKM (0.88) NR4A2PKMTSHRMAPK1USP2
SCHEMBL14967365 0.81 NR4A2 (0.73) NR4A2PKMTSHRMAPK1TP53
SCHEMBL10495056 0.79 RAB9A (0.65) NR4A2PKMTSHRMAPK1USP2
SCHEMBL9041802 0.77 PTPRC (0.59) NR4A2PKMMAPK1L3MBTL1MAPT
SCHEMBL4509186 0.76 PKM (0.78) NR4A2PKMTSHRMAPK1USP2
SCHEMBL20502046 0.76 PKM (0.78) NR4A2PKMTSHRMAPK1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
EP-1761486-A1 PHENYLCARBOXYLIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DIABETES Merck Patent GmbH (DE) 2007-03-14 EP disclosed
WO-2006000288-A1 PHENYLCARBOXYLIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 NR4A2 2394/4885PKM 990/4885MITF 2924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.